logo-loader
viewSeelos Therapeutics

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York.

Dr. Mehra says since listing on the exchange in January, the small company has achieved an 'incredible feat' by laying the groundwork to potentially be engaging in a pivotal study to treat orphan diseases and proof-of-concept studies to prevent and treat suicide and depression. 

Quick facts: Seelos Therapeutics

Price: 0.8933 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $24.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics receives grant money from research foundation to treat...

Team San Sanfilippo Foundation representatives told Proactive Investors the nonprofit medical research foundation has contributed grant money towards New York-based biotech Seelos Therapeutics Inc's (NASDAQ:SEEL) upcoming clinical study to treat Sanfillipo Syndrome. Team San Filippo...

on 07/15/2019

2 min read